alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 10.6
 NS GROUP, INC. EQUITY PLAN
RESTRICTED SHARES AGREEMENT
 Notice of Restricted Share Grant
     Terms of Agreement
 1. Grant of Restricted Shares
 2. Vesting of Restricted Shares
  Vesting Date
    
    Portion of Restricted
Shares
Vesting on such Vesting Date
   Page 1 of 4




---



##### 



Exhibit 10.6
 NS GROUP, INC. EQUITY PLAN
RESTRICTED SHARES AGREEMENT
 3. Forfeiture of Shares
 4. Transferability
 5. Dividend, Voting and Other Rights provided however
 6. Custody of Restricted Shares
 7. No Employment Contract
 Page 2 of 4




---



##### 



Exhibit 10.6
 NS GROUP, INC. EQUITY PLAN
RESTRICTED SHARES AGREEMENT
 8. Taxes and Withholding
 9. Compliance with Law provided however
 10. Amendments
 11. Severability
 12. Relation to Plan
 13. Successors and Assigns
 Page 3 of 4




---



##### 



Exhibit 10.6
 NS GROUP, INC. EQUITY PLAN
RESTRICTED SHARES AGREEMENT
 14. Governing Law
 15. Electronic Delivery.
  NS GROUP, INC.By:Name:Title:
  GranteeDate:
 Page 4 of 4
#### In the Matter of John C. R. Eckerson and Others, as Trustees, etc.

Motion to dismiss appeal denied, with ten dollars costs.
#### James Blute, Respondent, v. Cornelius C. Fellowes, Appellant.

Motion for reargument denied.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CORRECTIONAL
SYSTEMS, INC. FORM-KSB FOR THE FISCAL YEAR ENDED DECEMBER 31, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0001010032
<NAME> CORRECTIONAL SYSTEMS, INC.

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                         472,488
<SECURITIES>                                         0
<RECEIVABLES>                                  792,746
<ALLOWANCES>                                     5,000
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,328,309
<PP&E>                                       1,670,067
<DEPRECIATION>                                  98,371
<TOTAL-ASSETS>                               4,939,903
<CURRENT-LIABILITIES>                          759,667
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      3,364
<COMMON>                                         3,644
<OTHER-SE>                                   3,691,317
<TOTAL-LIABILITY-AND-EQUITY>                 4,939,903
<SALES>                                      6,731,006
<TOTAL-REVENUES>                             6,731,006
<CGS>                                                0
<TOTAL-COSTS>                                6,531,135
<OTHER-EXPENSES>                                62,759
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              57,960
<INCOME-PRETAX>                                116,727
<INCOME-TAX>                                    20,385
<INCOME-CONTINUING>                            137,112
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   116,727
<EPS-BASIC>                                        .03
<EPS-DILUTED>                                      .02


</TABLE>
#### Mary Ritter, Respondent, v. Acme Engineering and Contracting Company, Appellant.

Judgment and order reversed on the ground that the verdict is excessive, and new trial granted, with costs to appellant to abide event, unless the plaintiff stipulates to reduce the verdict to $1,500, in which case the judgment is modified and as so modified judgment and order affirmed, with costs.

All concurred, except Smith, P. J., and Betts, J., who voted for affirmance without modification.
<PAGE>

                                                                    Exhibit 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Fedders Corporation, a Delaware
corporation (the "Company"), on Form 10-Q for the Quarter ending November 30,
2003 as filed with the Securities and Exchange Commission (the "Report"), I, Sal
Giordano, Jr., Chief Executive Officer of the Company, certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that to
my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

/s/ Sal Giordano, Jr.
-----------------------
Sal Giordano, Jr.
Chief Executive Officer

Date: January 14, 2003

A signed original of this written statement required by Section 906 has been
provided to Fedders Corporation and will be retained by Fedders Corporation and
furnished to the Securities and Exchange Commission or its staff upon request.

                                       26
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000743456
<NAME> 83A4.TXT
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                         342,034
<SECURITIES>                                         0
<RECEIVABLES>                                  185,176
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               527,210
<PP&E>                                      17,819,592
<DEPRECIATION>                              13,255,427
<TOTAL-ASSETS>                               5,091,375
<CURRENT-LIABILITIES>                           91,376
<BONDS>                                              0
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   4,999,999
<TOTAL-LIABILITY-AND-EQUITY>                 5,091,375
<SALES>                                      1,085,474
<TOTAL-REVENUES>                             1,136,046
<CGS>                                                0
<TOTAL-COSTS>                                1,502,327
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 83,719
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             83,719
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    83,719
<EPS-PRIMARY>                                   (0.39)
<EPS-DILUTED>                                        0
        

</TABLE>
# Ralph E. Flanders: A Featured Biography

**

----

In a dramatic Senate floor speech on March 9, 1954, Vermont senator Ralph E. Flanders became one of the first members of the Republican Party to denounce fellow senator Joseph McCarthy’s methods in fighting communism. Flanders introduced the resolution that would eventually lead to McCarthy’s censure by the Senate on December 2, 1954. Reflecting on this battle, Flanders later wrote, “The conviction grew that something must be done about this, even if I had to do it myself.” During his two-term Senate career, Flanders served on a number of key committees, including Armed Services, Banking, and Finance. Although he had no official college diploma, Flanders received 16 honorary degrees and was an accomplished mechanical engineer and inventor in the field of machine tools from a young age until his death in 1970.

All Featured Biographies

        -  Contact 
        -  Leadership & Officers 
        -  Former Senators 
        -  Qualifications & Terms of Service 
        -  Facts & Milestones 
        -  States 

### Organizational Chart 

This chart shows the relationships among Senate leaders and officers who manage the flow of legislative and administrative business in the Senate.  

### Contact Your Senator 

Can't find your senator's name in the list of Senators?  Perhaps he or she is a member of the U.S. House of Representatives, or a Senator in your State Legislature.

### Biographical Directory 

The Directory provides information about former and current senators.
Exhibit 21.1




SUBSIDIARIES
      OF THE COMPANY







The
      following are subsidiaries of En Pointe Technologies, Inc.:





En
      Pointe
      Technologies Sales, Inc. (incorporated in Delaware)


En
      Pointe
      Gov, Inc. (incorporated in Delaware)


En
      Pointe
      Technologies Canada, Inc. (incorporated in Ontario, Canada)


The
      Xyphen Corporation (incorporated in California)


Ovex
      Technologies (Pvt) Limited (incorporated in Pakistan)


En
        Pointe
        Technologies India Pvt. Ltd., (incorporated in
        India)
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     3,439,247
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0


</TABLE>
<TABLE> <S> <C>

<ARTICLE>                        5
<LEGEND>
This schedule contains summary financial information extracted from the FaxSav
Incorporated Financial Statements, and is qualified in its entirety by reference
to such financial statements.
</LEGEND>

<S>                              <C>
<PERIOD-TYPE>                    12-MOS
<FISCAL-YEAR-END>                               DEC-31-1997
<PERIOD-END>                                    DEC-31-1997
<CASH>                                            3,680,185
<SECURITIES>                                              0
<RECEIVABLES>                                     2,610,843
<ALLOWANCES>                                        330,724
<INVENTORY>                                               0
<CURRENT-ASSETS>                                  5,996,148
<PP&E>                                            8,482,229
<DEPRECIATION>                                    4,306,965
<TOTAL-ASSETS>                                   10,495,585
<CURRENT-LIABILITIES>                             4,663,136
<BONDS>                                                   0
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                            108,065
<OTHER-SE>                                              (15)
<TOTAL-LIABILITY-AND-EQUITY>                     10,495,585
<SALES>                                          17,418,333
<TOTAL-REVENUES>                                 17,418,333
<CGS>                                            10,413,797
<TOTAL-COSTS>                                    14,298,322
<OTHER-EXPENSES>                                    (96,115)
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                  (78,769)
<INCOME-PRETAX>                                  (7,118,902)
<INCOME-TAX>                                              0
<INCOME-CONTINUING>                                       0
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                     (7,118,902)
<EPS-PRIMARY>                                          (.72)
<EPS-DILUTED>                                          (.72)



</TABLE>
<PAGE>   1

                                                                    EXHIBIT 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

     We consent to the incorporation by reference in the Registration Statement
(Form S-8 No. 333-30039) pertaining to the 1996 Stock Plan, Employee Stock
Purchase Plan and Non-Employee Directors' Stock Option Plan of Aurora
Biosciences Corporation of our report dated January 29, 1999, with respect to
the financial statements of Aurora Biosciences Corporation included in this
Annual Report (Form 10-K/A) for the year ended December 31, 1998.




                                                           /s/ ERNST & YOUNG LLP

San Diego, California
March 16, 2000
v150341_10-803 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing


     

    Exhibit
10.80.3
[ARTICLE] 5
<TABLE>
<S>                                          <C>                     <C>
[PERIOD-TYPE]                                3-MOS                   6-MOS
[FISCAL-YEAR-END]                          DEC-31-1996             DEC-31-1996
[PERIOD-END]                               SEP-30-1996             SEP-30-1996
[CASH]                                           2,839                   2,839
[SECURITIES]                                         0                       0
[RECEIVABLES]                                      169                     169
[ALLOWANCES]                                         0                       0
[INVENTORY]                                          0                       0
[CURRENT-ASSETS]                                 3,364                   3,364
[PP&E]                                          47,115                  47,115
[DEPRECIATION]                                  13,841                  13,841
[TOTAL-ASSETS]                                  56,507                  56,507
[CURRENT-LIABILITIES]                            1,824                   1,824
[BONDS]                                         45,451                  45,451
[PREFERRED-MANDATORY]                                0                       0
[PREFERRED]                                          0                       0
[COMMON]                                         4,011                   4,011
[OTHER-SE]                                      (1,244)                 (1,244)
[TOTAL-LIABILITY-AND-EQUITY]                    56,507                  56,507
[SALES]                                              0                       0
[TOTAL-REVENUES]                                 3,726                  24,439
[CGS]                                                0                       0
[TOTAL-COSTS]                                    3,534                  10,775
[OTHER-EXPENSES]                                     0                       0
[LOSS-PROVISION]                                     0                       0
[INTEREST-EXPENSE]                                 749                   2,445
[INCOME-PRETAX]                                   (557)                 11,219
[INCOME-TAX]                                       (8)                   4,808
[INCOME-CONTINUING]                               (549)                  6,419
[DISCONTINUED]                                       0                       0
[EXTRAORDINARY]                                      0                       0
[CHANGES]                                            0                       0
[NET-INCOME]                                      (549)                  6,419
[EPS-PRIMARY]                                     0.13                    1.53
[EPS-DILUTED]                                     0.13                    1.53
</TABLE>
II

106TH CONGRESS

2D SESSION S. 2374

To suspend temporarily the duty on certain TAED chemicals.

IN THE SENATE OF THE UNITED STATES

APRIL 6, 2000

Mr. HELMS introduced the following bill; which was read twice and referred

to the Committee on Finance

A BILL

To suspend temporarily the duty on certain TAED chemicals.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. TEMPORARY DUTY SUSPENSION.

4 (a) IN GENERAL.—Subchapter II of chapter 99 of

5 the Harmonized Tariff Schedule of the United States is

6 amended by inserting in numerical sequence the following

7 new heading:

‘‘ 9902.29.01 Tetraacetylethylenediamine (CAS

Nos. 10543–57–

4, 61791–28–4,

9004–32–4,

1328–53–6, 147–

14–8, 1302–78–

9, and 14808–

60–7) (provided

for in subheading

2924.10.10) ....... Free No change No change On or before

12/31/2004 ’’.
2

•S 2374 IS

1 (b) EFFECTIVE DATE.—The amendment made by

2 this section shall apply to goods entered, or withdrawn

3 from warehouse for consumption, on or after the 15th day

4 after the date of the enactment of this Act.

Æ
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 9
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                          13,767
<INT-BEARING-DEPOSITS>                             230
<FED-FUNDS-SOLD>                                31,000
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                    180,051
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                        238,052
<ALLOWANCE>                                      5,466
<TOTAL-ASSETS>                                 472,262
<DEPOSITS>                                     360,152
<SHORT-TERM>                                    31,512
<LIABILITIES-OTHER>                              7,994
<LONG-TERM>                                     10,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,780
<OTHER-SE>                                      60,824
<TOTAL-LIABILITIES-AND-EQUITY>                 472,262
<INTEREST-LOAN>                                 11,102
<INTEREST-INVEST>                                5,544
<INTEREST-OTHER>                                   472
<INTEREST-TOTAL>                                17,118
<INTEREST-DEPOSIT>                               7,199
<INTEREST-EXPENSE>                               8,342
<INTEREST-INCOME-NET>                            8,776
<LOAN-LOSSES>                                       10
<SECURITIES-GAINS>                                   0
<EXPENSE-OTHER>                                  4,945
<INCOME-PRETAX>                                  5,109
<INCOME-PRE-EXTRAORDINARY>                       5,109
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,522
<EPS-PRIMARY>                                      .79
<EPS-DILUTED>                                      .79
<YIELD-ACTUAL>                                    4.15
<LOANS-NON>                                        771
<LOANS-PAST>                                        85
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                      0
<ALLOWANCE-OPEN>                                 5,430
<CHARGE-OFFS>                                        6
<RECOVERIES>                                        32
<ALLOWANCE-CLOSE>                                5,466
<ALLOWANCE-DOMESTIC>                             2,895
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                          2,570
        

</TABLE>
# Senators Who Have Cast More than 10,000 Votes

**

----

Through April 20, 2023

*Statistics courtesy of the Senate Democratic Policy and Communications Center Vote Information Office*

        -  Contact 
        -  Leadership & Officers 
        -  Former Senators 
        -  Qualifications & Terms of Service 
        -  Facts & Milestones 
        -  States 

### Find Votes 

Find out about congressional voting with this How to guide.